Non-Small Cell Lung Cancer Coverage from Every Angle
Advertisement
Advertisement

Suresh S. Ramalingam, MD, on Comparing Maintenance Therapies in Non–Small Cell Lung Cancer: Less May Be More

Posted: Monday, June 24, 2019

Suresh S. Ramalingam, MD, of Emory University, discusses the value of negative research findings in light of the ECOG-ACRIN 5508 trial, which showed that the combination of pemetrexed and bevacizumab did not offer a survival benefit vs single agents in advanced nonsquamous NSCLC.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.